Drug Search Results
More Filters [+]

Sodelglitazar

Alternative Names: sodelglitazar, gw-677954, gw677954, gw 677954
Latest Update: 2017-03-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PPAR-d Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodelglitazar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Dyslipidemia|Metabolic Syndrome X|Type 2 Diabetes|Overweight|Hyperglycemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2005-001558-26

P2

Completed

Overweight

2007-06-25

ADG20001

P2

Completed

Type 2 Diabetes

2007-04-01

ADG106149

P2

Terminated

Type 2 Diabetes

2006-11-01

2006-001275-38

P2

Terminated

Hyperglycemia|Type 2 Diabetes

2006-10-20

Recent News Events

Date

Type

Title